Jarrod

Jarrod, on behalf of Geoff Meacham, asked about the impact of the management transition on R&D prioritization, specifically regarding the stability of the late-stage versus mid-stage pipeline. He also inquired about the potential for an accelerated regulatory filing for gotistobart if interim data proves positive.

Answer

Ramón Zapata, CFO, stated that the transition does not alter strategic R&D priorities, which remain focused on the late-stage pipeline and mRNA oncology programs, with governance structures providing stability. Özlem Türeci, CMO and Co-Founder, confirmed that if goti data replicates initial study results, there is potential for an accelerated regulatory path. Ugur Sahin, CEO and Co-Founder, added that the pipeline is rich, with a combination approach addressing multiple indications, and early-stage clinical data for new IO molecules and ADCs will be shared later this year or early next year.

Jarrod inquired about the stability of BioNTech's late-stage and mid-stage pipeline prioritization given the management transition, and whether positive interim data for gotistobart could lead to an accelerated regulatory filing.

Answer

CFO Ramón Zapata affirmed that the management transition does not alter BioNTech's strategic priorities, which remain focused on advancing the late-stage pipeline and mRNA oncology programs, supported by stable governance and scientific leadership. CMO Özlem Türeci confirmed that if the GOTI study data replicates initial results, there is potential for an accelerated approval pathway. CEO Ugur Sahin added that the pipeline is rich, with a combination approach, and early-stage clinical data will be shared later this year or early next.